Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
205
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report

Xujun LuDepartment of Pediatrics, Air Force Medical Center, Air Force Medical University, PLA, Beijing, 100142People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6124-7272View further author information
ORCID Icon &
Wenge WangDepartment of Pediatrics, Air Force Medical Center, Air Force Medical University, PLA, Beijing, 100142People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 1977-1981 | Received 24 May 2023, Accepted 19 Jul 2023, Published online: 29 Jul 2023

References

  • Armstrong AW, Read C, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
  • Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis. 2016;6:93–104. doi:10.2147/PTT.S101232
  • Lo Y, Tsai TF. Updates on the treatment of erythrodermic psoriasis. Psoriasis. 2021;11:59–73. doi:10.2147/PTT.S288345
  • Kacar N, Balci DD, Dogan S, et al. Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature. Asian Pac J Allergy Immunol. 2022. doi:10.12932/AP-241021-1259
  • Dastoli S, Passante M, Loconsole F, et al. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. J Dermatolog Treat. 2023;34(1):2200868. doi:10.1080/09546634.2023.2200868
  • Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022;36(7):e574–e576. doi:10.1111/jdv.18069
  • Neuhauser R, Eyerich K, Boehner A. Generalized pustular psoriasis-Dawn of a new era in targeted immunotherapy. Exp Dermatol. 2020;29(11):1088–1096. doi:10.1111/exd.14171
  • Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919. doi:10.1080/1744666X.2019.1648209
  • Carrasquillo OY, Pabon-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020;83(1):151–158. doi:10.1016/j.jaad.2020.03.073
  • Fotiadou C, Lazaridou E, Ioannides D. Management of psoriasis in adolescence. Adolesc Health Med Ther. 2014;5:25–34. doi:10.2147/AHMT.S36672
  • Carriero M. Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report. Drug Target Insights. 2022;16:1–5. doi:10.33393/dti.2022.2355
  • Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two Phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
  • Dogra S, Bishnoi A, Narang T, et al. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018;31(4):e12611. doi:10.1111/dth.12611
  • Zhao Z, Zhang X, Wang R, et al. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: a case report and brief literature review. Dermatol Ther. 2022;35(9):e15684. doi:10.1111/dth.15684
  • Pizzatti L, Mugheddu C, Sanna S, et al. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020;33(3):e13348. doi:10.1111/dth.13348

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.